Advanced search
Publication Cover
Acta Orthopaedica Volume 86, 2015 - Issue 1
Journal homepage
3,731
Views
132
CrossRef citations to date
0
Altmetric
Bisphosphonates and femoral fractures

Risk of atypical femoral fracture during and after bisphosphonate use

Full report of a nationwide study

Jörg SchilcherOrthopedics Section, Department of Clinical and Experimental Medicine, Faculty of Health Sciences, Linköping University, LinköpingCorrespondence[email protected]
,
Veronika KoeppenOrthopedics Section, Department of Clinical and Experimental Medicine, Faculty of Health Sciences, Linköping University, LinköpingCorrespondence[email protected]
,
Per AspenbergOrthopedics Section, Department of Clinical and Experimental Medicine, Faculty of Health Sciences, Linköping University, LinköpingCorrespondence[email protected]
&
Karl MichaëlssonOrthopedics Section, Department of Surgical Sciences and Uppsala Clinical Research Center, Uppsala University, Uppsala, SwedenCorrespondence[email protected]
Pages 100-107 | Received 29 Apr 2014, Accepted 04 Jun 2014, Published online: 13 Jan 2015

  • Bergstrom MF , Byberg L , Melhus H , Michaelsson K , Gedeborg R . Extent and consequences of misclassified injury diagnoses in a national hospital discharge registry. Inj Prev 2011; 17 (2): 108-13.
  • Black DM , Kelly MP , Genant HK , Palermo L , Eastell R , Bucci-Rechtweg C , et al. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med 2010; 362 (19): 1761-71.
  • Black DM , Bauer DC , Schwartz AV , Cummings SR , Rosen CJ . Continuing bisphosphonate treatment for osteoporosis--for whom and for how long? N Engl J Med 2012; 366 (22): 2051-3.
  • Charlson ME , Pompei P , Ales KL , MacKenzie CR . A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40 (5): 373-83.
  • Cummings SR , Black DM , Thompson DE , Applegate WB , Barrett-Connor E , Musliner TA , et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998; 280 (24): 2077-82.
  • Curtis JR , Westfall AO , Cheng H , Lyles K , Saag KG , Delzell E . Benefit of adherence with bisphosphonates depends on age and fracture type: results from an analysis of 101,038 new bisphosphonate users. J Bone Miner Res 2008; 23 (9): 1435-41.
  • Dell RM , Adams AL , Greene DF , Funahashi TT , Silverman SL , Eisemon EO , et al. Incidence of atypical nontraumatic diaphyseal fractures of the femur. J Bone Miner Res 2012; 27 (12): 2544-50.
  • Eastell R , Walsh JS , Watts NB , Siris E . Bisphosphonates for postmenopausal osteoporosis. Bone 2011; 49 (1): 82-8.
  • Ebetino FH , Hogan AM , Sun S , Tsoumpra MK , Duan X , Triffitt JT , et al. The relationship between the chemistry and biological activity of the bisphosphonates. Bone 2011; 49 (1): 20-33.
  • Ettinger B , Burr DB , Ritchie RO . Proposed pathogenesis for atypical femoral fractures: lessons from materials research. Bone 2013; 55 (2): 495-500.
  • Feldstein AC , Weycker D , Nichols GA , Oster G , Rosales G , Boardman DL , et al. Effectiveness of bisphosphonate therapy in a community setting. Bone 2009; 44 (1): 153-9.
  • Feldstein AC , Black D , Perrin N , Rosales AG , Friess D , Boardman D , et al. Incidence and demography of femur fractures with and without atypical features. J Bone Miner Res 2012; 27 (5): 977-86.
  • Gedmintas L , Solomon DH , Kim SC . Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: a systematic review and meta-analysis. J Bone Miner Res 2013; 28 (8): 1729-37.
  • Girgis CM , Sher D , Seibel MJ . Atypical femoral fractures and bisphosphonate use. N Engl J Med 2010; 362 (19): 1848-9.
  • Giusti A , Hamdy NA , Papapoulos SE . Atypical fractures of the femur and bisphosphonate therapy: A systematic review of case/case series studies. Bone 2010; 47 (2): 169-80.
  • Greenland SR , Rothman K. J . Introduction to Stratified Analysis In: Modern Epidemiology, Third Edition. (Ed. Rothman KJG , Lash S. , T. L. ). Lippincott Williams and Wilkins: Philadelphia; 2008.
  • Inderjeeth CA , Foo AC , Lai MM , Glendenning P . Efficacy and safety of pharmacological agents in managing osteoporosis in the old old: review of the evidence. Bone 2009; 44 (5): 744-51.
  • Ing-Lorenzini K , Desmeules J , Plachta O , Suva D , Dayer P , Peter R . Low-energy femoral fractures associated with the long-term use of bisphosphonates. Drug Saf 2009; 32 (9): 775-85.
  • Kharazmi M , Michaelsson K , Hallberg P . Prodromal symptoms in patients with bisphosphonate-associated atypical fractures of the femur. J Bone Miner Metab 2014 [Epub ahead of print].
  • Ludvigsson JF , Andersson E , Ekbom A , Feychting M , Kim JL , Reuterwall C , et al. External review and validation of the Swedish national inpatient register. BMC public health 2011; 11: 450.
  • Meier RP , Perneger TV , Stern R , Rizzoli R , Peter RE . Increasing occurrence of atypical femoral fractures associated with bisphosphonate use. Arch Intern Med 2012; 172 (12): 930-6.
  • Norman TL , Wang Z . Microdamage of human cortical bone: incidence and morphology in long bones. Bone 1997; 20 (4): 375-9.
  • Odvina CV , Zerwekh JE , Rao DS , Maalouf N , Gottschalk FA , Pak CY . Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005; 90 (3): 1294-301.
  • . Quan H , Sundararajan V , Halfon P , Fong A , Burnand B , Luthi J , et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005; 43 (11): 1130-9.
  • Rose G , Hamilton PJ . A randomised controlled trial of the effect on middle-aged men of advice to stop smoking. J Epidemiol Community Health 1978; 32 (4): 275-81.
  • Rosen CJ , Hochberg MC , Bonnick SL , McClung M , Miller P , Broy S , et al. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res 2005; 20 (1): 141-51.
  • Rydholm A . Highly different risk estimates for atypical femoral fracture with use of bisphosphonates - debate must be allowed! Acta Orthop. 2012; 83 (4): 319-20.
  • Schilcher J . Epidemiology, radiology and histology of atypical femoral fractures. Acta Orthop Suppl 2013; 84 (352): 1-26.
  • Schilcher J , Aspenberg P . Incidence of stress fractures of the femoral shaft in women treated with bisphosphonate. Acta Orthop 2009; 80 (4): 413-5.
  • Schilcher J , Michaelsson K , Aspenberg P . Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 2011; 364 (18): 1728-37.
  • Schilcher J , Koeppen V , Ranstam J , Skripitz R , Michaelsson K , Aspenberg P . Atypical femoral fractures are a separate entity, characterized by highly specific radiographic features. A comparison of 59 cases and 218 controls. Bone 2013; 52 (1): 389-92.
  • Schilcher J , Koeppen V , Aspenberg P , Michaelsson K . Risk of atypical femoral fracture during and after bisphosphonate use. N Engl J Med 2014a; 371 (10): 974-6.
  • Schilcher J , Sandberg O , Isaksson H , Aspenberg P . Histology of 8 atypical femoral fractures. Acta Orthop 2014b: 1-7.
  • Seeman E . Bone quality: the material and structural basis of bone strength. J Bone Miner Metab 2008; 26 (1): 1-8.
  • Shane E , Burr D , Abrahamsen B , Adler RA , Brown TD , Cheung AM , et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the american society for bone and mineral research. J Bone Miner Res 2014; 29 (1): 1-23.
  • Silverman SL , Schousboe JT , Gold DT . Oral bisphosphonate compliance and persistence: a matter of choice? Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2011; 22 (1): 21-6.
  • Sim Ie W , Ebeling PR . Treatment of osteoporosis in men with bisphosphonates: rationale and latest evidence. Therapeutic advances in musculoskeletal disease 2013; 5 (5): 259-67.
  • Talley C , Kushner HI , Sterk CE . Lung cancer, chronic disease epidemiology, and medicine , 1948-1964. Journal of the history of medicine and allied sciences 2004; 59 (3): 329-74.
  • U.S. Department of Health and Human Services . The Health Consequences of Smoking: A Report of the Surgeon General. The Health Consequences of Smoking: A Report of the Surgeon General.: Atlanta, GA: U.S.; 2004.
  • Valimaki MJ , Karkkainen M , Lamberg-Allardt C , Laitinen K , Alhava E , Heikkinen J , et al. Exercise, smoking, and calcium intake during adolescence and early adulthood as determinants of peak bone mass. Cardiovascular Risk in Young Finns Study Group. BMJ (Clinical research ed) 1994; 309 (6949): 230-5.
  • Wells G , Cranney A , Peterson J , Boucher M , Shea B , Robinson V , et al. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 2008a; (1): CD004523.
  • Wells GA , Cranney A , Peterson J , Boucher M , Shea B , Robinson V , et al. Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 2008b; (1): CD003376.
  • Wells GA , Cranney A , Peterson J , Boucher M , Shea B , Welch V , et al. Alendronate for preventing fractures caused by osteoporosis in postmenopausal women. Cochrane Database Syst Rev 2008c; (1): CD001155.
  • Whitaker M , Guo J , Kehoe T , Benson G . Bisphosphonates for osteoporosis--where do we go from here? N Engl J Med 2012; 366 (22): 2048-51.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.